The following slide deck was published by Agile Therapeutics, Inc. in conjunction with this Read more ...

Back in May, Agile Therapeutics ( AGRX ), publicized that they resubmitted Twirla’s NDA to FDA. Twirla is Agile’s lead product candidate that is a low-dose combination hormonal contraceptive patch. Subsequently, Agile stated that the FDA accepted the NDA resubmission with t...

PRINCETON, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,...